Cantor Fitzgerald Forecasts RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings per share of ($4.44) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $118.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.15) per share.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. The business’s revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.23) earnings per share.

Other research analysts have also recently issued reports about the stock. Piper Sandler lifted their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. TD Cowen raised their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. decreased their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, December 24th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $92.43.

Ultragenyx Pharmaceutical Stock Up 4.0 %

Shares of NASDAQ:RARE opened at $42.94 on Wednesday. The stock’s 50 day moving average is $44.63 and its 200-day moving average is $49.59. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of -6.64 and a beta of 0.58.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. KBC Group NV lifted its holdings in shares of Ultragenyx Pharmaceutical by 2,275.8% in the fourth quarter. KBC Group NV now owns 61,010 shares of the biopharmaceutical company’s stock worth $2,567,000 after buying an additional 58,442 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Ultragenyx Pharmaceutical by 1.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after acquiring an additional 294 shares during the period. Nordea Investment Management AB lifted its stake in Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company’s stock worth $1,658,000 after purchasing an additional 3,246 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after purchasing an additional 76,150 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 8,273 shares of Ultragenyx Pharmaceutical stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the transaction, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. The trade was a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.80% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.